Zota Health Valuation

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>ZH</div>
ZOTA -- India Stock  

INR 143.65  1.55  1.09%

How much is Zota Health Care worth today? Zota Health Care maintains a prevalent Real Value of 142.73 per share. The last-minute price of the company is 143.65. At this time, the company appears to be fairly valued. Our model calculates the value of Zota Health Care from examining the company fundamentals such as return on asset of 4.46 %, current valuation of 3.69 B, and profit margin of 3.44 % as well as analyzing its technical indicators and Probability Of Bankruptcy. In general, we encourage buying undervalued securities and selling overvalued securities since, at some point, asset prices and their ongoing real values will grow together.

Search Valuation

Zota Health Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Zota Health's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Fairly Valued
10th of July 2020
Real Value
Zota Health is very steady asset. Calculation of real value of Zota Health Care is based on 3 months time horizon. Increasing Zota Health Care time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Band Projection (param)
LowerMiddle BandUpper
LowEstimated ValueHigh
Annual Dividend
LowIncome Per ShareHigh

Zota Health Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Zota Health's current stock value. Our valuation model uses many indicators to compare Zota Health value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Zota Health competition to find correlations between indicators driving Zota Health's intrinsic value. More Info.
Zota Health Care is rated first in price to book category among related companies. It is rated first in beta category among related companies totaling about  0.13  of Beta per Price to Book. The ratio of Price to Book to Beta for Zota Health Care is roughly  7.52 

About Zota Health Valuation

The Macroaxis Equity Valuation Mechanism determines the current worth of Zota Health Care on a weekly bases. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Zota Health Care. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Zota Health Care based exclusively on its fundamental and basic technical indicators. By analyzing Zota Health's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Zota Health's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Zota Health. We calculate exposure to Zota Health's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Zota Health's related companies.
Zota Health Care Limited manufactures and markets pharmaceutical products in India and internationally. The company was founded in 1995 and is headquartered in Surat, India. Zota Health operates under Biotechnology classification in India and is traded on National Stock Exchange of India. It employs 370 people.
Check out Your Current Watchlist. Please also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page